Immunogene therapy of tumors with a vaccine based on the ligand-binding domain of chicken homologous integrin β3

Yanyan Lou, Yu Quan Wei, Li Yang, Xia Zhao, Ling Tian, You Lu, Yan Jun Wen, Fen Liu, Mei Juan Huang, Bin Kang, Fei Xiao, Jing Mei Su, Qu Ming He, Xing Jiang Xie, Yun Qiu Mao, Song Lei, Ji Yan Liu, Fen Lou, Li Qun Zhou, Feng PengYu Jiang, Bing Hu

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The breaking of immune tolerance against angiogenesis-associated molecules should be a useful approach for cancer therapy by active immunity. We used chicken integrin β3 as a model antigen to explore the feasibility of immunogene therapy of the tumors with a vaccine based on a single xenogeneic homologous gene, targeting the molecules associated with angiogenesis. To test this concept we constructed a plasmid DNA encoding the ligand-binding domain of chicken integrin β3 (P-BD-C) and control vectors. We found that immunogene therapy of tumors with a vaccine based on the ligand-binding domain of chicken integrin β3 (P-BD-C) was effective in both protective and therapeutic anti-tumor immunity in several tumor models in mice. Autoantibodies against integrin β3 in sera of mice immunized with the ligand-binding domain of chicken integrin β3 could be found by Western blot analysis and ELISA assay. The purified immunoglobulins were effective in the inhibition of endothelial cell proliferation in vitro, and in anti-tumor activity as well as in the inhibition of angiogenesis by adoptive transfer in vivo. The anti-tumor activity and the production of integrin β3-specific autoantibodies (manifested by significantly elevated Ig G1 and Ig G2b) could be abrogated by the depletion of CD4+ T lymphocytes. These observations may provide a vaccine strategy for cancer therapy through the induction of the autoimmunity against the molecules associated with tumor growth in a cross-reaction with a single xenogeneic homologous gene and may be of importance in the further exploration of the applications of other xenogeneic homologous genes identified in human and other animal genome sequence projects in cancer therapy.

Original languageEnglish (US)
Pages (from-to)51-69
Number of pages19
JournalImmunological Investigations
Volume31
Issue number1
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Integrins
Chickens
Vaccines
Ligands
Neoplasms
Therapeutics
Autoantibodies
Active Immunity
Immune Tolerance
Cancer Vaccines
Gene Targeting
Adoptive Transfer
Cross Reactions
Autoimmunity
Genes
Immunoglobulins
Immunity
Plasmids
Endothelial Cells
Western Blotting

ASJC Scopus subject areas

  • Immunology

Cite this

Immunogene therapy of tumors with a vaccine based on the ligand-binding domain of chicken homologous integrin β3 . / Lou, Yanyan; Wei, Yu Quan; Yang, Li; Zhao, Xia; Tian, Ling; Lu, You; Wen, Yan Jun; Liu, Fen; Huang, Mei Juan; Kang, Bin; Xiao, Fei; Su, Jing Mei; He, Qu Ming; Xie, Xing Jiang; Mao, Yun Qiu; Lei, Song; Liu, Ji Yan; Lou, Fen; Zhou, Li Qun; Peng, Feng; Jiang, Yu; Hu, Bing.

In: Immunological Investigations, Vol. 31, No. 1, 2002, p. 51-69.

Research output: Contribution to journalArticle

Lou, Y, Wei, YQ, Yang, L, Zhao, X, Tian, L, Lu, Y, Wen, YJ, Liu, F, Huang, MJ, Kang, B, Xiao, F, Su, JM, He, QM, Xie, XJ, Mao, YQ, Lei, S, Liu, JY, Lou, F, Zhou, LQ, Peng, F, Jiang, Y & Hu, B 2002, 'Immunogene therapy of tumors with a vaccine based on the ligand-binding domain of chicken homologous integrin β3 ', Immunological Investigations, vol. 31, no. 1, pp. 51-69. https://doi.org/10.1081/IMM-120003221
Lou, Yanyan ; Wei, Yu Quan ; Yang, Li ; Zhao, Xia ; Tian, Ling ; Lu, You ; Wen, Yan Jun ; Liu, Fen ; Huang, Mei Juan ; Kang, Bin ; Xiao, Fei ; Su, Jing Mei ; He, Qu Ming ; Xie, Xing Jiang ; Mao, Yun Qiu ; Lei, Song ; Liu, Ji Yan ; Lou, Fen ; Zhou, Li Qun ; Peng, Feng ; Jiang, Yu ; Hu, Bing. / Immunogene therapy of tumors with a vaccine based on the ligand-binding domain of chicken homologous integrin β3 In: Immunological Investigations. 2002 ; Vol. 31, No. 1. pp. 51-69.
@article{0a3e2f17e30d49f18d5d2a36ff456c2e,
title = "Immunogene therapy of tumors with a vaccine based on the ligand-binding domain of chicken homologous integrin β3",
abstract = "The breaking of immune tolerance against angiogenesis-associated molecules should be a useful approach for cancer therapy by active immunity. We used chicken integrin β3 as a model antigen to explore the feasibility of immunogene therapy of the tumors with a vaccine based on a single xenogeneic homologous gene, targeting the molecules associated with angiogenesis. To test this concept we constructed a plasmid DNA encoding the ligand-binding domain of chicken integrin β3 (P-BD-C) and control vectors. We found that immunogene therapy of tumors with a vaccine based on the ligand-binding domain of chicken integrin β3 (P-BD-C) was effective in both protective and therapeutic anti-tumor immunity in several tumor models in mice. Autoantibodies against integrin β3 in sera of mice immunized with the ligand-binding domain of chicken integrin β3 could be found by Western blot analysis and ELISA assay. The purified immunoglobulins were effective in the inhibition of endothelial cell proliferation in vitro, and in anti-tumor activity as well as in the inhibition of angiogenesis by adoptive transfer in vivo. The anti-tumor activity and the production of integrin β3-specific autoantibodies (manifested by significantly elevated Ig G1 and Ig G2b) could be abrogated by the depletion of CD4+ T lymphocytes. These observations may provide a vaccine strategy for cancer therapy through the induction of the autoimmunity against the molecules associated with tumor growth in a cross-reaction with a single xenogeneic homologous gene and may be of importance in the further exploration of the applications of other xenogeneic homologous genes identified in human and other animal genome sequence projects in cancer therapy.",
author = "Yanyan Lou and Wei, {Yu Quan} and Li Yang and Xia Zhao and Ling Tian and You Lu and Wen, {Yan Jun} and Fen Liu and Huang, {Mei Juan} and Bin Kang and Fei Xiao and Su, {Jing Mei} and He, {Qu Ming} and Xie, {Xing Jiang} and Mao, {Yun Qiu} and Song Lei and Liu, {Ji Yan} and Fen Lou and Zhou, {Li Qun} and Feng Peng and Yu Jiang and Bing Hu",
year = "2002",
doi = "10.1081/IMM-120003221",
language = "English (US)",
volume = "31",
pages = "51--69",
journal = "Immunological Investigations",
issn = "0882-0139",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Immunogene therapy of tumors with a vaccine based on the ligand-binding domain of chicken homologous integrin β3

AU - Lou, Yanyan

AU - Wei, Yu Quan

AU - Yang, Li

AU - Zhao, Xia

AU - Tian, Ling

AU - Lu, You

AU - Wen, Yan Jun

AU - Liu, Fen

AU - Huang, Mei Juan

AU - Kang, Bin

AU - Xiao, Fei

AU - Su, Jing Mei

AU - He, Qu Ming

AU - Xie, Xing Jiang

AU - Mao, Yun Qiu

AU - Lei, Song

AU - Liu, Ji Yan

AU - Lou, Fen

AU - Zhou, Li Qun

AU - Peng, Feng

AU - Jiang, Yu

AU - Hu, Bing

PY - 2002

Y1 - 2002

N2 - The breaking of immune tolerance against angiogenesis-associated molecules should be a useful approach for cancer therapy by active immunity. We used chicken integrin β3 as a model antigen to explore the feasibility of immunogene therapy of the tumors with a vaccine based on a single xenogeneic homologous gene, targeting the molecules associated with angiogenesis. To test this concept we constructed a plasmid DNA encoding the ligand-binding domain of chicken integrin β3 (P-BD-C) and control vectors. We found that immunogene therapy of tumors with a vaccine based on the ligand-binding domain of chicken integrin β3 (P-BD-C) was effective in both protective and therapeutic anti-tumor immunity in several tumor models in mice. Autoantibodies against integrin β3 in sera of mice immunized with the ligand-binding domain of chicken integrin β3 could be found by Western blot analysis and ELISA assay. The purified immunoglobulins were effective in the inhibition of endothelial cell proliferation in vitro, and in anti-tumor activity as well as in the inhibition of angiogenesis by adoptive transfer in vivo. The anti-tumor activity and the production of integrin β3-specific autoantibodies (manifested by significantly elevated Ig G1 and Ig G2b) could be abrogated by the depletion of CD4+ T lymphocytes. These observations may provide a vaccine strategy for cancer therapy through the induction of the autoimmunity against the molecules associated with tumor growth in a cross-reaction with a single xenogeneic homologous gene and may be of importance in the further exploration of the applications of other xenogeneic homologous genes identified in human and other animal genome sequence projects in cancer therapy.

AB - The breaking of immune tolerance against angiogenesis-associated molecules should be a useful approach for cancer therapy by active immunity. We used chicken integrin β3 as a model antigen to explore the feasibility of immunogene therapy of the tumors with a vaccine based on a single xenogeneic homologous gene, targeting the molecules associated with angiogenesis. To test this concept we constructed a plasmid DNA encoding the ligand-binding domain of chicken integrin β3 (P-BD-C) and control vectors. We found that immunogene therapy of tumors with a vaccine based on the ligand-binding domain of chicken integrin β3 (P-BD-C) was effective in both protective and therapeutic anti-tumor immunity in several tumor models in mice. Autoantibodies against integrin β3 in sera of mice immunized with the ligand-binding domain of chicken integrin β3 could be found by Western blot analysis and ELISA assay. The purified immunoglobulins were effective in the inhibition of endothelial cell proliferation in vitro, and in anti-tumor activity as well as in the inhibition of angiogenesis by adoptive transfer in vivo. The anti-tumor activity and the production of integrin β3-specific autoantibodies (manifested by significantly elevated Ig G1 and Ig G2b) could be abrogated by the depletion of CD4+ T lymphocytes. These observations may provide a vaccine strategy for cancer therapy through the induction of the autoimmunity against the molecules associated with tumor growth in a cross-reaction with a single xenogeneic homologous gene and may be of importance in the further exploration of the applications of other xenogeneic homologous genes identified in human and other animal genome sequence projects in cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=0036230027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036230027&partnerID=8YFLogxK

U2 - 10.1081/IMM-120003221

DO - 10.1081/IMM-120003221

M3 - Article

C2 - 11990463

AN - SCOPUS:0036230027

VL - 31

SP - 51

EP - 69

JO - Immunological Investigations

JF - Immunological Investigations

SN - 0882-0139

IS - 1

ER -